Enliven Therapeutics (ELVN) Stock Price, News & Analysis

Company Overview

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Key Stats

• Today's Range: $20.79 to $22.36
• 50-Day Range: $19.62 to $24.42
• 52-Week Range: $10.90 to $30.03
• Volume: 325,326 shs
• Average Volume: 235,003 shs
• Market Capitalization: $1.05 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $38.25
• Consensus Rating: Buy

Enliven Therapeutics Stock Analysis - MarketRank™

Enliven Therapeutics scored higher than 38% of companies evaluated by MarketBeat, and ranked 723rd out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Enliven Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Enliven Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Enliven Therapeutics are expected to decrease in the coming year, from ($1.95) to ($2.35) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Enliven Therapeutics is -11.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Enliven Therapeutics is -11.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Enliven Therapeutics has a P/B Ratio of 3.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

23.57% of the float of Enliven Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Enliven Therapeutics has a short interest ratio ("days to cover") of 34.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Enliven Therapeutics has recently increased by 4.64%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Enliven Therapeutics does not currently pay a dividend.

Dividend Growth

Enliven Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

23.57% of the float of Enliven Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Enliven Therapeutics has a short interest ratio ("days to cover") of 34.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Enliven Therapeutics has recently increased by 4.64%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: -0.07

News Sentiment

Enliven Therapeutics has a news sentiment score of -0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Enliven Therapeutics this week, compared to 4 articles on an average week.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Enliven Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $949,435.00 in company stock.

Percentage Held by Insiders

29.20% of the stock of Enliven Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

95.08% of the stock of Enliven Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ELVN Stock Analysis - Frequently Asked Questions

How have ELVN shares performed this year?

Enliven Therapeutics' stock was trading at $22.50 at the beginning of the year. Since then, ELVN stock has decreased by 4.6% and is now trading at $21.46.
View the best growth stocks for 2025 here.

How were Enliven Therapeutics' earnings last quarter?

Enliven Therapeutics, Inc. (NASDAQ:ELVN) released its earnings results on Tuesday, August, 13th. The company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.17.

Who are Enliven Therapeutics' major shareholders?

Top institutional shareholders of Enliven Therapeutics include FMR LLC (13.29%), Polar Capital Holdings Plc (4.89%), Vanguard Group Inc. (4.04%) and 5AM Venture Management LLC (3.34%). Insiders that own company stock include Joseph P Lyssikatos, Samuel Kintz, 5Am Partners Vi, Llc, Anish Patel, Rishi Gupta, Rahul D Ballal and Benjamin Hohl.
View institutional ownership trends.

How do I buy shares of Enliven Therapeutics?

Shares of ELVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Enliven Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Enliven Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), Broadcom (AVGO), Tesla (TSLA) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 8/13/2024
• Today: 3/06/2025
• Next Earnings (Estimated): 3/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ELVN
• CIK: 1672619
• Web: imaratx.com
• Phone: 617-927-9989
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $38.25
• High Stock Price Target: $42.00
• Low Stock Price Target: $34.00
• Potential Upside/Downside: +78.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-71,580,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -29.46%
• Return on Assets: -27.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 17.44
• Quick Ratio: 17.44

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.97 per share
• Price / Book: 3.59

Miscellaneous

• Outstanding Shares: 48,859,000
• Free Float: 34,592,000
• Market Cap: $1.05 billion
• Optionable: Optionable
• Beta: 1.04